Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40
Junxiang Wang(Tongji Hospital), Gang Chen(Fudan University), Ying Xiang(Ministry of Education of the People's Republic of China), Daniel Ricklin(University of Basel), John D. Lambris(University of Pennsylvania), Lu Wang(Children's Hospital of Philadelphia)
Cited by 16
Related Papers
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
|Cellular Physiology and Biochemistry|2017|4.1k
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
|The Oncologist|2003|576
Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense
|Immunological Reviews|2016|510
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
|Clinical Infectious Diseases|2020|501